$SCOR

SCOR reports 24% drop in second quarter net income By Investing.com

SCOR SE reported Q2 net income of EUR 171 million, down 24% year over year, with insurance revenue down 5.1%. The property and casualty combined ratio improved to 79.5% on lower catastrophe losses and better attritional performance. Life and health service result was hurt by a one-off arbitration outcome. SCOR posted EUR 397 million net income in H1 2026 and expects continued competitive P&C reinsurance conditions.

Original reporting
Published Jul 30, 2026, 5:23 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 5:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$SCOR
Bearish
medium confidence
Mentioned
$SCOR
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$SCORBearishMed
01

Why it matters

The key tradable takeaway is the mix of weaker top-line and profit decline versus underwriting improvement (lower catastrophe activity, better attritional losses) and ongoing capital guidance.

02

Market read

A quantified earnings datapoint with segment drivers and guidance language that can reprice near-term expectations for reinsurance profitability and capital generation.

03

What to watch

The life and health result was hit by a one-off negative arbitration outcome, which could mean normalized earnings are less weak than headline net income suggests.

Relevance 7/10Novelty 7/10Timing: post-Q2 results, ahead of next earnings cycle

Background

SCOR is a French reinsurer reporting Q2 2026 results, including net income, revenue, underwriting metrics, and investment income commentary.

Company-level read

Ticker impact

$SCORBearishMedium confidence
Context

SCOR reported Q2 net income down 24% YoY to EUR 171 million, with insurance revenue down 5.1% and segment impacts cited.

Expected impact

Near-term downside bias versus prior expectations unless investors focus on combined-ratio improvement and capital guidance.

Evidence & confidence

The article provides multiple quantified operating drivers (net income, revenue, combined ratio, arbitration outcome) plus forward-looking guidance language on capital generation and reinvestment rates.

Market effects

Reinsurer read-through: underwriting profitability (combined ratio) and investment income assumptions remain key swing factors.

Primarily European insurance/reinsurance sentiment; could influence EUR-denominated financials risk appetite.

Limited direct global spillover beyond reinsurance pricing and capital generation expectations.

Counterpoint

Investors may discount the net income decline if the P&C combined ratio improvement and capital generation on track indicate underlying underwriting resilience.

Key entities

  • SCOR SE

    Reported Q2 2026 net income of EUR 171 million, down 24% YoY, with P&C combined ratio improving to 79.5% and guidance on capital generation and reinvestment rates.

Related articles

$SCORMed

Why is SCOR stock rallying today? By Investing.com

SCOR SE shares rose about 3.5% to 34.58 on Euronext Paris after the company reported Q2 2026 results. SCOR posted net income of EUR 171 million in Q2 and EUR 397 million for the first half, with a property and casualty combined ratio of 79.5%. Morgan Stanley named SCOR a preferred European insurance pick, citing potential capital release from Solvency II changes in Jan 2027.

$SCORMedAI 9/10

SCOR successfully places EUR 500 million subordinated notes maturing in 2056

SCOR SE said it has placed EUR 500 million fixed-to-floating rate subordinated notes maturing 5 June 2056, eligible as Solvency II Tier 2 capital. The notes pay 4.510% annually until 5 June 2036, then 3-month EURIBOR plus a margin quarterly, with possible interest deferral. Moody’s rates them A3. Proceeds will fund general purposes and a concurrent EUR 250 million tender for 2047 notes; settlement expected 5 June 2026.

$SCORMedAI 9/10

SCOR announces the launch of a cash tender offer and its intention to issue new subordinated notes

SCOR SE said it launched a cash tender offer to buy EUR 250m Fixed to Reset Subordinated Notes due 2047 (ISIN FR0012770063; EUR 250m outstanding) and EUR 500m Fixed to Reset Subordinated Notes due 2048 (ISIN FR0013179314; EUR 500m outstanding). The offer runs 27 May–3 June 2026. SCOR also intends to issue new Tier 2-eligible subordinated notes, with proceeds funding the tender, subject to market conditions.

$USNAHighAI 9/10

Why Usana Health Sciences Stock Plummeted This Week

Usana Health Sciences (USNA) shares fell about 30% after its Aug. 4 Q2 results missed expectations and guidance disappointed. The company reported non-GAAP EPS of $0.07 on about $223M sales, with sales and profit below analyst averages. It also took a $29M goodwill impairment on Hiya, cut 2024 guidance to an $11M loss and lowered sales to $910M from $925M-$1B.